Peptide Technologies acquires wound healing IP for 150M shares and $10M deferred cash

REGENEREX PHARMA, INC.

Acquired Wound Healing Technology Platform from Gregory P. Pilant and Deborah L. Pilant for 150M restricted common shares and $10M deferred cash.
Cash payment of $10M to be funded from future revenue or investment, due within 60 months, with no interest.
Closing deadline set for November 25, 2021 (within 10 days of signing on November 15, 2021).
Technology platform includes drug candidates and biological solutions for chronic wound care in humans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.